Retroviral IFN-α gene transfer combined with gemcitabine acts synergistically via cell cycle alteration in human pancreatic carcinoma cells implanted orthotopically in nude mice

Journal of Interferon and Cytokine Research

Volumn 24, Issue 8, 2004, Pages 490-496

  Ziske, Carsten ^a,d   Nagaraj, Srinivas ^a   Märten, Angela ^b   Gorschlüter, Marcus ^a   Strehl, John ^a   Sauerbruch, Tilman ^a   Abraham, Nader G ^c   Schmidt Wolf, Ingo G H ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c WESTCHESTER MEDICAL CENTER   (United States)

^d UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; GEMCITABINE; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; GENE EXPRESSION; GENE TRANSFER; GENETIC CODE; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMPLANTATION; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS CANCER; PANCREAS CARCINOMA; PRIORITY JOURNAL; RETROVIRUS; TUMOR VOLUME; VIRUS GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DNA, COMPLEMENTARY; FEMALE; GENE EXPRESSION; GENE THERAPY; HUMANS; INTERFERON-ALPHA; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; RETROVIRIDAE; TRANSGENES;

ANIMALIA; MUS MUSCULUS; UNIDENTIFIED RETROVIRUS;

EID: 4344678062     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/1079990041689647     Document Type: Article

References (21)

1. HERTZOG, P., HWANG, S. Y., and KOLA, I. (1994). Role of interferons in the regulation of cell proliferation, differentation, and development. Mol. Reprod. Dev. 39, 226-232.
2. WAGENER, D.J., WILS, J.A., KOK, T.C., PLANTING, A., COUVREUR, M.L., and BARON, B. (2002). Results of a randomised phase II study of cisplatin plus 5-fluorouracil versus cisplatin plus 5-fluorouracil with alpha-interferon in metastatic pancreatic cancer: an EORTC gastrointestinal tract cancer group trial. Eur. J. Cancer 38, 648-653.
3. VON HOFF, D.D., and GREEN, M.R. (1996). Gemcitabine HcL: combined efficacy and tolerability in managing the solid tumor patient. Semin. Oncol. 23 (Suppl. 10):1-100.
4. CASPER, E.S., GREEN, M.R., KELSEN, D.P., HEELAN, R.T., BROWN, T.D., FLOMBAUM, C.D., TROCHANOWSKI, B., and TARASSOFF, P.G. (1994). Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest. New Drugs 12, 29-34.
5. CARMICHAEL, J., FINK, U., RUSSELL, R. C., SPITTLE, M. F., HARRIS, A. L., SPIESSI, G., and BLATTER, J. (1996). Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br. J. Cancer 73, 101-105.
6. SHI, X., LIU, S., KLEEFF, J., FRIESS, H., and BUCHLER, M. W. (2002). Acquired resistance of pancreatic cancer cells towards 5-fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 62, 354-362.
7. ZOLI, W., RICOTTI, L., BARZANTI, F., DAL SUSINO, M., FRASSINETTI, L., MILANDRI, C., GIUNCHI, D., and AMADORI, D. (1999). Schedule dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines. Int. J. Cancer 80, 413-416.
8. ROCKWELL, S. (1977). In vivo-in vitro tumor systems: new models for studying the response of tumors to therapy. Lab. Anim. Sci. 27, 831-851.
9. TWENTYMAN, P.R., WATSON, J.V., BLEEHEN, N.M., and ROWLES, P.M. (1975). Changes in cell proliferation kinetics occurring during the life history of monolayer cultures of a mouse tumour cell line. Cell Tissue Kinet. 8, 41-50.
10. HEINEMANN, V., SCHULZ, L., ISSELS, R.D., and PLUNKETT, W. (1995). Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. Semin. Oncol. 22, 11-18.
11. SABAAWY, H.E., FARLEY, T., AHMED, T., FELDMAN, E., and ABRAHAM, N. G. (1999). Synergetic effects of retrovirus IFN-alpha gene transfer and 5-FU on apoptosis of colon cancer cells. Acta Haematol. 101, 82-88.
12. SABAAWY, H.M., IKEHARA, S., ADACHI, Y., QUAN, S., FELDMAN, E., KANCHERLA, R., ABRAHAM, N.G., and AHMED, T. (1999). Enhancement of 5-fluorouracil cytotoxicity on human colon cancer cells by retrovirus-mediated interferon-alpha gene transfer. Int. J. Oncol. 14, 1143-1151.
13. OGURA, H., TANI, K., OZAWA, K., NAGATA, S., ASANO, S., and TAKAKU, F. (1990). Implantation of genetically manipulated fibroblasts into mice as antitumor alpha-interferon therapy. Cancer Res. 50, 5102-5106.
14. TOWERS, G.J., STOCKHOLM, D., LABROUSSE-NAJBURG, V., CARLIER, F., DANOS, O., and PAGES, J.C. (1999). One step screening of retroviral producer clones by real time quantitative PCR. J. Gene Med. 1, 352-359.
15. PESTIEAU, S.R., STUART, O.A., CHANG, D., JACQUET, P., and SUGARBAKER, P.H. (1998). Pharmacokinetics of intraperitoneal gemcitabine in a rat model. Tumori 84, 706-711.
16. COHEN, A., MINSKY, B., and SCHIISKY, R. Cancer, Principles and Practices of Oncology, 4th ed. Philadelphia: Lippincott, 1993.
17. MILLER, A.D., TRAUBER, D.R., and BUTTIMORE, C. (1986). Factors involved in production of helper virus-free retrovirus vectors. Somatic Cell Mol. Genet. 12, 175-183.
18. + cells maintains regeneration capacity and enhances adhesion molecules in K562 cells. J. Invest. Med. 47, 414-424.
19. BELLDEGRUN, A., TSO, C.L., SAKATA, T., DUCKETT, T., BRUNDA, M.J., BARSKY, S.H., CHAI, J., KABOO, R., LAVEY, R.S., McBRIDE, W.H., et al. (1993). Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): implications for live cancer vaccines. J. Natl. Cancer Inst. 85, 207-216.
20. PITHA, P.M. (1990). Interferons: a new class of tumor suppressor genes? Cancer Cells 2, 215-216.
21. EGUCHI, H., NAGANO, H., YAMAMOTO, H., MIYAMOTO, A., KONDO, M., DONO, K., NAKAMORI, S., UMESHITA, K., SAKON, M., and MONDEN, M. (2000). Augmentation of antitumor activity of 5-fluorouracil by interferon alpha is associated with up-regulation of p27Kip1 in human hepatocellular carcinoma cells. Clin. Cancer Res. 6, 2881-2890.